Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. The WHO has rated migraine amongst the top 20 most disabling life time conditions. Migraine is a pervasive and debilitating, chronic neurological painful disorder, affecting from 15% to 29% of the general population. It is the second most common cause of headache characterized by recurrent episodes of headache and associated symptoms i.e. nausea, sensitivity to light and noise that typically last from 4 to 72 hours which is divided into four phases. Migraine is well explained with three hypothesis i.e., vascular, platelet, central nervous system. It affects people of all groups, sexes, races and social classes around the globe. Migraine can occur due to various trigger factors and can be managed with both pharmacological and non-pharmacological treatment.
INTRODUCTION
Migraine is a pervasive and debilitating, chronic neurological painful disorder, affecting from 15% to 29% of the general population (10% of adult population in United States) (Alvin et. al. 1979) . Migraine is the second most common cause of headache characterized by recurrent episodes of headache and associated symptoms i.e., nausea, sensitivity to light and noise that typically last from 4 to 72 hours. Pain management of migraine includes both non-pharmacological and pharmacologic methods for acute episodes and prophylaxis. Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage (Terry J. Baumann,2005) . Pain is a dynamic complex process which is generally classified in terms of nociceptive and neuropathic pathways, migraine pain is a neuropathic pathways which is quite different from nociceptive pain which is sustained by abnormal processing of sensory input by peripheral or CNS, a large number neuropathic pain syndromes exist and clinically ,they are often difficult to treat (pasero et al ,1999) patients presents with spontaneous pain transmissions often described as tingling, burning, shockline or shooting, exaggerated painful response to normally non-noxious stimuli (Allodynia) (pasero et al 1999, Elliott,1994) or painful repoint to noxious stimuli (hyperalgesia).
On an average a migraineur experiences around 13 attacks per year which may vary from person to person. The WHO has rated migraine amongst the top 20 most disabling life time conditions. It affects people of all groups, sexes, races and social classes around the globe. Migraine can occur due to various trigger factors like stress, emotions, environmental factors, genetic factors, diet, sleep disturbances hormonal factors (menstruation, oral contraceptives) (www.migraine.org.uk/triggers).
PATHOPHYSIOLOGY
According to vascular hypothesis proposed by Harold Wolff in 1938, the migraine aura is caused by intracerebral arterial vasoconstrictions that is followed by reactive extra-cranial vasodilatation and associated headache. Migraine without aura is a neurobiological disorder (J Olesen et al,2004) and pain is believed to result from activity within trigeminal nucleus results in release of vasoactive neuropeptides, particularly calcitonin gene-related peptide (CGRP), Neurokinin A, and substance P, from perivascular axons. The released neuropeptides interact with dural blood vessels to promote vasodilatation and dural plasma extravasations, Migraine genes identified by studying families with familial hemiplegic migraine (FHM) which involves gene mutations CACNA1A of calcium voltage gated (50%) and SCN1A of Na + /K + ATPase (20%). Data also support a role for dopamine in pathophysiology of certain sub types of migraine which induces stimulation so dopaminergic antagonists show effective therapeutic agents against migraine. Pharmacological data supports the serotonin (5-HT) as antimigraine therapy (Peter J Goadsby et al,2005) . Coming to platelet hypothesis, which involves abnormal platelet activation with relevant characteristics like: a. They do not adhere to one another unless precipitated; b. Certain stimuli (catecholamines, thromboxane A2 and ADP. c. Once aggregates form; they release a portion of contents (eg. Serotonin, adenosine and its phosphate derivatives).
Prostaglandin produced by platelets (thromboxane A2) and vascular endothelium (prostacyclin) produces vasoconstriction and vasodilatation (Deshmukh 1977, Meyer) . This platelet hyperaggregability forms micro-emboli that lodge in microvasculature release their contents cause changes in vasomotor tone which induce tissue response leading to migraine pain. Platelets which is a primary blood source of serotonin where a rapid decline in plasma levels occur in initiation and during migraine attack which is indicated with increase in metabolite of serotonin, urinary 5-hydroxyindoleacetic acid which indicate serotonin release during migraine attacks whereas this does not occur in other headache types and not a reaction to pain, stress and vomiting (Rydzewski 1978 , Saito et al 1987 . Serotonin enhance sensitivity to pain receptors leading to vascular permeability where pain producing substance release at site leading to inflammatory response in migraine attacks (Glover et al, 1982) , according to central nervous system hypothesis it is a disturbance with secondary vasomotor changes in CNS, it is initiation of neurologic symptoms occurs primarily in cerebral cortex and progressed gradually with cerebral depression (Olesen ,1985) . Migraine attacks can be precipitated centrally with psychological stress, fatigue excitation of neural pathways by environmental stimuli (i.e., Noise, Glare). From above discussion it is evident that no complete satisfying description of pathologic events associated with migraine exists. Migraine is general classified by International Headache Society shown below in flowchart (Olesen et al, 2004 , www.ihs.org). 
Stages of Migraine Attack:
In human beings, migraine is different, which includes five stages that distinguish migraine from another headache.
Premonitory or warning phase:
It is also known as prodrome phase were certain physical and mental changes such as tiredness, mood changes, feeling thirsty and a stiff neck. This symptom lasts about 1 to 24 hrs.
Aura phase:
This stage includes a wide range of neurological symptoms lasting for 5 to 60 minutes, where migraine without aura does not include. Symptoms include dark or colored spots, numbness, vertigo, speech and hearing disturbance, confusion, partial paralysis. Around 20% children and young people experience "aura".
Main attack:
In this phase, you will have cephalgia or abdominal pain, nausea, vomiting decrease in concentration and sensitive to light or sound.
Resolution /Postdrome stage:
This phase is the final stage of attack; symptoms mimic first stage and lasting about hours or days to disappear the feeling of hangover or tiredness (www.migrainetrust.org).
Diagnosis of Migraine:
Migraine can be diagnosed on the basis of frequency and number of attacks and associated with typical warning signs and symptoms. It is typically manifest by episodic headache though it is more than just head pain.
Differential Diagnosis:
Migraine is typically diagnosed from Tension Type Headache (TTH) as it lasts about hours or days as TTH is chronic present more often. Migraine varies from cluster headache with unilateral headache with autonomic dysfunction and other type is medication overuse headache (MOH) which is transformed into chronic daily headache similar to that of chronic TTH with some migrainous features. According to International Headache Society Criteria, migraine is of two types: Migraine with Aura ( 
Examination and Investigations:
The main goal of examination and investigation is to consider brain disease and to screen out hypertension and depression along with exclusion of causes of migraine like symptoms but no tests to confirm migraine. Investigations include brain scan which is referral to find the early diagnosing of neurological disorders which provides impossible workload of 18% women, 6% men have migraine, 3% have chronic daily headache.
Other tests include erythrocyte sedimentation rate (ESR) in early headache of geriatrics which address temporal arteritis and chest X-ray in smokers to consider metastatic cancer. 
PAIN MANAGEMENT OF MIGRAINE

Cognitive Behavioral Therapy (CBT):
It is based on principle that anxiety and distress are aggravators of an evolving migraine headache.it is designed to help patient identify and modify maladaptive response that may trigger or aggravate a migraine headache (Selby,1960) . Stress management training is often part of treatment. CBT is usually combined with other behavioural therapies but it is more effective as its own (Bakal et al. 1981 , Richardson 1989 Kakigi et al., 2005) . It has potential effect as therapeutic intervention in various chronic disease conditions. Yogic breathing is a unique method for balancing the autonomic nervous system and influencing psychologic and stress-related disorders (Mel, 2002) . This practice of yoga is carried in prodromal stage and not in resolution and postdromal stage (John et al 2007) .
Other Supplement Treatments:
Some of the vitamins as well as mineral supplements are responsible in treatment of migraine which is observed in scientific studies that potentiates the treatment. Riboflavin: It is vitamin B 2 , which is important for energy metabolism. The rationale for using riboflavin is that it helps in boost brain metabolism. It is taken about 400 mg per day. Melatonin: It is used as homeopathic sleep aid and to help with jet lag, but no significant studies in treating migraine or other headache, useful in treating sleep disturbances. It is taken 3-6 mg at bedtime. Magnesium: Magnesium has wide function in our body, fluctuations in levels of magnesium results in triggers of migraine. It is given about 300-500 mg per day. Co-Enzyme Q10: It is very essential constituent of cells that involves metabolism. In migraine triggers it is used to increase Q10 levels that increase brain metabolism. It is given about 300-600 mg per day (www.hartp.neurology.ucla.edu). . Over the counter combinations of acetaminophen, caffeine and aspirin was approved for treating migraine in US due to its efficacy in relieving migraine pain and its associated symptom more than simple analgesics (Fettes 1999 , Weitzel, 1999 Step 3 Opioid for moderate to severe pain, ± non-opioid adjuvant Morphine, Oxycodone, Fentanyl, NSAIDS/ Cox -2 Inhibitors
Step 4 Nerve block, epidural, neurolytic nerve blocks, PCA pump
ANTI -EMETICS:
Adjunctive antiemetic therapy is useful for combating the nausea and vomiting that accompany migraine headache and medication used to treat acute attacks eg: ergotamine tartrate, dihydroergotamine and ergotamine are useful in treating moderate to severe attacks of migraine contraindicated in patients with history of ischemic heart disease, uncontrolled hypertension, cerebrovascular diseases and they are also contraindicated in patients with hemiplegic and basilar migraine. Concomitant therapy with Selective Serotonin Reuptake Inhibitors (SSRI) should be carefully monitored because of isolated reports of serotonin syndrome in sumatriptan treated patients. This drugs have revolutionized many lives of severe migraine and act as powerful option for migraine attack .These are available various dosage forms like sprays, tablets, injections and suppositories . Sumatriptan is contraindicated in pregnancy and lactation as it is less teratogenic but with high preterm births (Evans, 2008) and even excreted in breast milk (Horton et al. 1996) . Almotriptan 12.5 mg has shown to abate migraine attack effectively when given in early phase of attack within 1 hour (Goadsby, 2008).
Prophylactic Treatment: β -blockers are widely used drugs for migraine prophylaxis with intrinsic sympathomimetic activity are ineffective for migraine prophylaxis. β blockers are used with caution in patients with cardiovascular diseases and asthma. They reduce the brain cell activities which are involved in migraine. These are generally available in tablets and capsules forms (www.migrainetrust.org). Amitriptyline is anti-depressant used in migraine prophylaxis it reduces frequency, severity and duration of migraine attacks (Ramadan, 2000). Other tricyclic anti-depressants have shown beneficial effects in small doses in treating migraine prophylaxis. They acts as antagonist of 5-HT 2 receptor or suppresses serotonergic neuronal activity in brain stem (Silberstein 2000 . Anticonvulsants (valproic acid and divalproex sodium) 1:1 can reduce frequency of headaches by atleast 50% in up to 65% of migraineurs. Its mechanism is unclear in migraine (Silberstein 2002). Calcium channel blockers, among this class verapamil is a drug of choice for prevention of migraine it is generally considered as second or third-line prophylactic agent with established clinical benefit are ineffective or contraindicated (Silberstein 2000, Goadsby 2000) and flunarizine (sibelium) which is generally prescribed by specialist. These drugs reduce calcium entry into neurons making them less excitable and blocks dopamine receptors in brain. (www.migrainetrust.org)
NEW DEVELOPMENTS IN MIGRAINE THERAPY
Botulinum toxin type A: (onabotulinum toxin A; BTA) It inhibits the release of acetylcholine at motor nerve terminals (Simpson, 1981) . This action led to its use in the treatment of movement disorders, such as dystonia, post-stroke spasticity and hyperhidrosis (Jankovic, 2004 ) and neuropathic pain, lower back pain, myofascial pain, bladder pain (www.migrainetrust.org). Its cosmetic use suggests the potential benefits in headache. Basic experimental studies showed anti-nociceptive properties in some standard models, such as rats with formalin-induced pain, (Cui et al., 2004) which provided the rationale for its development in headache prevention (Aoki, 2005) . According to rami burstein, botulinum toxin inhibits pain in chronic migraine by reducing expression of certain pain pathways involving nerve cells in trigeminovascular system that plays a key role in the headache phase of migraine attack.
Neuromodulation: Neuromodulatory approaches are currently focusing on the stimulation of the Greater Occipital Nerve (GON). The targeted synapses and neurons are located in the trigeminocervical complex and receive convergent input from the GON as well as from the trigeminal nerve (Doare et al, 2006) . The functional imaging studies have shown that central processing of migraine pain signals in the thalamus could be modified by GON stimulation (Matharu et al, 2004) . The use of occipital nerve stimulation for the treatment of intractable head pain in human beings was first proposed in 1999, when a series of cases of intractable occipital neuralgia responding to occipital nerve stimulation were reported (Weiner et al, 1999) these device (gamma core) a trans cutaneous vagus nerve stimulator is placed on the sides of neck where the stimulation is increased slowly and muscles contractions are felt under skin. It is held about 90 seconds.
 Pain relief in 20 % of patients within 2 hours of use  Recovery from disability caused by migraine  Relief of sickness, photophobia and phonophobia.( www.migrainetrust.org)
